Testosterone enanthate therapy is effective and independent of SRD5A2 and AR gene polymorphisms in boys with micropenis

被引:16
|
作者
Ishii, T
Sasaki, G
Hasegawa, T
Sato, S
Matsuo, N
Ogata, T
机构
[1] Natl Res Inst Child Hlth & Dev, Dept Endocrinol & Metab, Tokyo 1548567, Japan
[2] Keio Univ, Sch Med, Dept Pediat, Tokyo 108, Japan
关键词
penis/abnormalities; testosterone; 5-alpha-reductase; polymorphism (genetics);
D O I
10.1097/01.ju.0000129005.84831.1e
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We report penile length (PL) responses to testosterone enanthate (TE) therapy for micropenis, and the relevance of the V89L polymorphism of SRD5A2 encoding the 5alpha-reductase type 2 and CAG repeat length polymorphism of AR encoding the androgen receptor. Materials and Methods: A total of 53 Japanese boys with micropenis (less than -2.0 SD) 0 to 13 years old who had no SRD5A2 or AR mutation were examined. TE was given at a dosage of 25 mg intramuscularly, and PL was measured at least 4 weeks after the injection. The 2 polymorphisms were determined by direct sequencing. Results: PLs became -2.0 SD or greater in all the boys after TE therapy (1 injection in 4 boys, 2 in 28, 3 in 19 and 4 in 2), with a significant increase in the medians of PLs (from 2.5 to 3.5 cm, p <0.0001) and SD score, (from -2.6 to -0.7, p <0.0001). The increment in actual PL at the first injection ranged from 0.2 to 1.5 cm (median 0.6) and was independent of age (r = 0.22, p = 0.12) and body surface area (r = 0.11, p =0.43), while that in PL SD score at the first injection ranged from 0.3 to 2.5 (1.0) and was inversely correlated with age (r = -0.33, p = 0.02) and body surface area (r = -0.37, p = 0.008). The actual PL increment at the first injection was also unrelated to initial PL (r = -0.03, p = 0.81). The median of actual PL increments at the first injection was similar among boys with V/V, V/L and L/L genotypes of SRD5A2 (0.6 cm in 18, 0.7 cm in 30 and 0.5 cm in 5, respectively, p = 0.77), and between boys with and without long CAG repeats (26 or greater) of AR (0.65 cm in 6 and 0.6 cm in 47, respectively, p = 0.77). In addition, there was no significant correlation between actual PL increment at the first injection and CAG repeat length (r = 0.06, p = 0.67). Conclusions: Our results suggest that administration of 25 mg TE is effective for micropenis in prepubertal boys with no SRD5A2 or AR mutation, with variable but significant PL increments, and that the penile responsiveness to TE therapy is independent of the V89L and the CAG repeat length polymorphisms.
引用
收藏
页码:319 / 323
页数:5
相关论文
共 11 条
  • [1] Steroid 5-α-Reductase Type 2 (SRD5a2) Gene Polymorphisms and Risk of Prostate Cancer: A HuGE Review
    Li, Jun
    Coates, Ralph J.
    Gwinn, Marta
    Khoury, Muin J.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2010, 171 (01) : 1 - 13
  • [2] A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH
    Klotsman, M
    Weinberg, CR
    Davis, K
    Binnie, CG
    Hartmann, KE
    PHARMACOGENOMICS JOURNAL, 2004, 4 (04) : 251 - 259
  • [3] AR and SRD5A2 gene mutations in a series of 51 Turkish 46,XY DSD children with a clinical diagnosis of androgen insensitivity
    Akcay, T.
    Fernandez-Cancio, M.
    Turan, S.
    Gueran, T.
    Audi, L.
    Bereket, A.
    ANDROLOGY, 2014, 2 (04) : 572 - 578
  • [4] Molecular Characterization of Two Known SRD5A2 Gene Variants in Mexican Patients With Disorder of Sexual Development
    Maria Guadalupe, Ortiz-Lopez
    Katy, Sanchez-Pozos
    Charmina, Aguirre-Alvarado
    Vihko, Pirkko
    Marta, Menjivar
    FRONTIERS IN GENETICS, 2022, 12
  • [5] Male pseudohermaphroditism resulting from a novel mutation in the human steroid 5 alpha-reductase type 2 gene (SRD5A2)
    Anwar, R
    Gilbey, SG
    New, JP
    Markham, AF
    JOURNAL OF CLINICAL PATHOLOGY-MOLECULAR PATHOLOGY, 1997, 50 (01): : 51 - 52
  • [6] A 5α-reductase (SRD5A2) polymorphism is associated with serum testosterone and sex hormone-binding globulin in men, while aromatase (CYP19A1) polymorphisms are associated with oestradiol and luteinizing hormone reciprocally
    Yeap, Bu B.
    Knuiman, Matthew W.
    Handelsman, David J.
    Ho, Ken K. Y.
    Hui, Jennie
    Divitini, Mark L.
    Arscot, Gillian M.
    McQuillan, Brendan
    Hung, Joseph
    Beilby, John P.
    CLINICAL ENDOCRINOLOGY, 2019, 90 (02) : 301 - 311
  • [7] Longer (TA)n Repeat but Not A49T and V89L Polymorphisms in SRD5A2 Gene May Confer Prostate Cancer Risk in South Indian Men
    Rajender, Singh
    Vijayalakshmi, Krishnaswamy
    Pooja, Singh
    Madhavi, Sakhamuri
    Paul, Solomon F. D.
    Vettriselvi, V.
    Shroff, Sunil
    Singh, Lalji
    Thangaraj, Kumarasamy
    JOURNAL OF ANDROLOGY, 2009, 30 (06): : 703 - 710
  • [8] Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy
    Wang, Zongwei
    Deng, Tuo
    Long, Xingbo
    Lin, Xueming
    Wu, Shulin
    Wang, Hongbo
    Ge, Rongbin
    Zhang, Zhenwei
    Wu, Chin-Lee
    Taplin, Mary-Ellen
    Olumi, Aria F.
    PLOS ONE, 2020, 15 (03):
  • [9] Two genetic variants in the SRD5A2 gene are found to be associated with sex differences in the disease characteristics of patients with chronic hepatitis B virus infection
    Duan, Honglei
    Wang, Xu
    Qi, Wenqian
    Shi, Jingyi
    Han, Liang
    Wang, Guohua
    Xu, Yanhui
    Liu, Jia
    Wang, Jiangbin
    BIOLOGY OF SEX DIFFERENCES, 2023, 14 (01)
  • [10] Single-nucleotide polymorphism in the 5-α-reductase gene (SRD5A2) is associated with increased prevalence of metabolic syndrome in chemotherapy-treated testicular cancer survivors
    Boer, Hink
    Westerink, Nico-Derk L.
    Altena, Renske
    Nuver, Janine
    Dijck-Brouwer, D. A. Janneke
    van Faassen, Martijn
    Klont, Frank
    Kema, Ido P.
    Lefrandt, Joop D.
    Zwart, Nynke
    Boezen, H. Marike
    Smit, Andries J.
    Meijer, Coby
    Gietema, Jourik A.
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : 104 - 111